Evaluation of The Cost Effectiveness and Societal Impact of Rifaximin-Á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In The Netherlands
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.2219
https://www.valueinhealthjournal.com/article/S1098-3015(15)04295-3/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
1636
First Page :
A629
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04295-3&doi=10.1016/j.jval.2015.09.2219